Functionalized Hyaluronic Acid for "In Situ" Matrix Metalloproteinase Inhibition: A Bioactive Material to Treat the Dry Eye Sydrome.

MLA

Burgalassi, Susi, et al. “Functionalized Hyaluronic Acid for ‘In Situ’ Matrix Metalloproteinase Inhibition: A Bioactive Material to Treat the Dry Eye Sydrome.” ACS Macro Letters, vol. 11, no. 10, Oct. 2022, pp. 1190–94. EBSCOhost, https://doi.org/10.1021/acsmacrolett.2c00455.

APA

Burgalassi, S., Fragai, M., Francesconi, O., Cerofolini, L., Monti, D., Leone, G., Lamponi, S., Greco, G., Magnani, A., & Nativi, C. (2022). Functionalized Hyaluronic Acid for “In Situ” Matrix Metalloproteinase Inhibition: A Bioactive Material to Treat the Dry Eye Sydrome. ACS Macro Letters, 11(10), 1190–1194. https://doi.org/10.1021/acsmacrolett.2c00455

Chicago

Burgalassi, Susi, Marco Fragai, Oscar Francesconi, Linda Cerofolini, Daniela Monti, Gemma Leone, Stefania Lamponi, Giuseppe Greco, Agnese Magnani, and Cristina Nativi. 2022. “Functionalized Hyaluronic Acid for ‘In Situ’ Matrix Metalloproteinase Inhibition: A Bioactive Material to Treat the Dry Eye Sydrome.” ACS Macro Letters 11 (10): 1190–94. doi:10.1021/acsmacrolett.2c00455.